K-V Pharmaceutical Company Receives Notification From New York Stock Exchange Of Compliance With Quantitative Continued Listing Standards
September 2, 2010 - September 2, 2010, St. Louis, MO. - K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that it has received notification from the New York Stock Exchange (“NYSE”) stating that the Company has reestablished compliance with the NYSE’s minimum share price requirements for continued listing on an accelerated basis.

K-V Pharmaceutical Company Announces the Election of New Independent Member to Board of Directors
August 9, 2010 - August 9, 2010, 5t. Louis, MO. - K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that Mr. Robert Baldini was appointed as a new independent member of the Board of Directors by a unanimous vote of the directors, which also voted to increase the size of the Board to eight directors.

K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants
August 3, 2010 - August 3, 2010, St. Louis, MO. – K-V Pharmaceutical Company (NYSE: KVa.KVb) announced today that the Audit Committee of its Board of Directors has engaged BDO USA, LLP (“BDO”) as the Company’s independent registered accounting firm.

ETHEX Corporation Initiated Nationwide Voluntary Recall of a Single Lot of Hydromorphone HCl 2 mg Tablets
December 23, 2008

KV Pharmaceutical Voluntarily Suspends All Shipments of its Approved Tablet-form Drugs
December 23, 2008

For additional press releases, go to the press release archive.